Patient and Payer Considerations in Parkinson Disease Psychosis to Optimize Population Health Outcomes: A Multistakeholder Panel Discussion

Author(s)Maria Lopes, MD, MS, Fernando L. Pagan, MD, Bhavesh Shah, RPh, BCOP

This publication was sponsored by Acadia Pharmaceuticals Inc.

This clinical brief provides insights from a panel of stakeholders about Parkinson disease (PD) and the prevalence and care of PD psychosis (PDP). The experts also offer key information about PDP from the payer and clinical perspectives.

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Patient and Payer Considerations in Parkinson Disease Psychosis to Optimize Population Health Outcomes: A Multistakeholder Panel Discussion

Trending on AJMC

NYC Legionnaires Disease Cluster Slows as Cooling Tower Remediation Continues

Medicaid Fraud Crackdown Intensifies, But Is It Solving the Right Problem?

Provider Trust, Social Media Use Can Shape Vaccine Myth Belief

MS Likely Unfolds Along a Continuum Years Before First Symptoms

FDA Approves Gedatolisib for HR+/HER2- Advanced Breast Cancer

Access, Affordability, & Accountability: A New Era in Oncology Reimbursement

Patient and Payer Considerations in Parkinson Disease Psychosis to Optimize Population Health Outcomes: A Multistakeholder Panel Discussion

Trending on AJMC

NYC Legionnaires Disease Cluster Slows as Cooling Tower Remediation Continues

Medicaid Fraud Crackdown Intensifies, But Is It Solving the Right Problem?

Provider Trust, Social Media Use Can Shape Vaccine Myth Belief

MS Likely Unfolds Along a Continuum Years Before First Symptoms

FDA Approves Gedatolisib for HR+/HER2- Advanced Breast Cancer